Biotherapeutics Discovery & Development
Transformational technologies to design, construct, and optimize biotherapeutics
- Informed protein design optimizes bioactivity and molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentiations
Bioconjugation technologies
Nucleic acid delivery technologies
- Nanoparticles, polymers and protein conjugations
Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
Structure-based and computational design of therapeutics including Artificial Intelligence and Machine Learning.
- Novel computational technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)
Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
Technologies and patient sample access for antibody discovery from human antibody responses
Targeted delivery technologies that address/overcome cell/tissue selectivity, cell membrane penetration, cross blood brain barrier
Integrated service providers to support early discovery activities for development of therapeutics
Broadly applicable platforms to enhance speed/quality of antibody generation
Novel biologics, combination therapies, and mRNA therapeutics that fit Pfizer strategies